Heron Therapeutics
(NASDAQ) HRTX
Heron Therapeutics Financials at a Glance
Market Cap
$150.85M
Revenue (TTM)
$154.90M
Net Income (TTM)
$20.20M
EPS (TTM)
$-0.12
P/E Ratio
-6.64
Dividend
$0.00
Beta (Volatility)
1.60 (High)
Dividend
$0.00
Beta (Volatility)
1.60 (High)
Price
$0.80
Volume
18,979
Open
$0.76
Price
$0.80
Volume
18,979
Open
$0.76
Previous Close
$0.80
Daily Range
$0.76 - $0.81
52-Week Range
$0.74 - $2.61
Dividend
$0.00
Beta (Volatility)
1.60 (High)
Price
$0.80
Volume
18,979
Open
$0.76
Previous Close
$0.80
Daily Range
$0.76 - $0.81
52-Week Range
$0.74 - $2.61
HRTX News
HRTX: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Heron Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
128
CEO
Craig A. Collard
Website
www.herontx.comHeadquarters
Cary, CA 92121, US
HRTX Financials
Key Financial Metrics (TTM)
Gross Margin
73%
Operating Margin
-2%
Net Income Margin
-13%
Return on Equity
0%
Return on Capital
-2%
Return on Assets
-8%
Earnings Yield
-15.06%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$150.85M
Shares Outstanding
188.54M
Volume
18.98K
Short Interest
0.00%
Avg. Volume
1.82M
Financials (TTM)
Gross Profit
$113.56M
Operating Income
$2.54M
EBITDA
$17.88M
Operating Cash Flow
$27.59M
Capital Expenditure
$317.00K
Free Cash Flow
$27.91M
Cash & ST Invst.
$46.63M
Total Debt
$140.64M
Heron Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$40.59M
-0.5%
Gross Profit
$32.94M
+7.8%
Gross Margin
81.15%
N/A
Market Cap
$150.85M
N/A
Market Cap/Employee
$1.24M
N/A
Employees
122
N/A
Net Income
$2.95M
-180.6%
EBITDA
$792.00K
-109.1%
Quarterly Fundamentals
Net Cash
$94.01M
+20.7%
Accounts Receivable
$89.59M
+13.6%
Inventory
$92.75M
+74.5%
Long Term Debt
$140.64M
-19.5%
Short Term Debt
$0.00
-100.0%
Return on Assets
-7.89%
N/A
Return on Invested Capital
-1.59%
N/A
Free Cash Flow
$9.18M
+26.0%
Operating Cash Flow
$9.18M
+22.0%